Study of serum 3,5,3′-triiodothyronine sulfate concentration in patients with systemic non-thyroidal illness
Abstract
Sulfation is an important pathway of triiodothyronine (T3) metabolism. Increased serum T3 sulfate (T3S) values have been observed during fetal life and in pathological conditions such as hyperthyroidism and selenium deficiency. Similar variations have also been reported in a small number of patients with systemic non-thyroidal illness, but the underlying mechanisms have not been elucidated. In this study, serum T3S concentrations have been measured by a specific radioimmunoassay in 28 patients with end-stage neoplastic disease (ESND) and in 44 patients with chronic renal failure (CRF); 41 normal subjects served as controls. Both ESND and CRF patients had lower serum total T4 (TT4) and total T3 (TT3) than normal controls, while serum reverse T3 (rT3) was increased significantly in ESND (0.7 +/- 0.5 nmol/l; p < 0.001 vs. controls) but not in CRF (0.3 +/- 0.1 nmol/l). The TT3/rT3 ratio, an index of type I iodothyronine monodeiodinase (type I MD) activity, was reduced significantly in both groups of patients. Serum T4-binding globulin (TBG) was decreased in CRF but not in ESND patients. Serum T3S was significantly higher both in ESND (71 +/- 32 pmol/l) and CRF (100 +/- 24 pmol/l) than in controls (50 +/- 16 pmol/l, p < 0.001). Serum T3S values showed a positive correlation with rT3 values and a negative correlation with both TT3 and FT3 values in ESND, but not in CRF. In the latter group a positive correlation was observed between T3S and TBG values. The T3S/FT3 ratio was higher both in CRF (18 +/- 5) and in ESND (23 +/- 18) as compared to controls (10 +/- 4). Serum inorganic sulfate was increased and correlated positively with T3S values in CRF patients. In conclusion, the results of this study in a large series of patients confirm that patients with systemic non-thyroidal illness have increased serum T3S levels. The mechanisms responsible for these changes appear to be different in ESND and CRF patients. In ESND the increase in serum T3S levels is mainly related to reduced degradation of the hormone by type I MD, whereas in CRF it might be driven by the enhanced sulfate ion concentration, and could be partially dependent on the impaired renal excretion of T3S. Because T3S can be reconverted to T3, it is possible that increased T3S concentrations contribute to maintenance of the euthyroid state in systemic non-thyroidal disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There are 2 metabolites from T3S: bioactive T3 via desulfation or bioinactive 3,3′-diiodothyronine sulfate generated by deiodinase type 1.
“There are 2 metabolites from T3S: bioactive T3 via desulfation or bioinactive 3,3′-diiodothyronine sulfate generated by deiodinase type 1.”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [176]
Sulfation of T3 (T3S) can enhance its solubility and stability.
“The sulfation of T3 (T3S) can enhance its solubility and stability (176).”
From Levothyroxine: conventional and novel drug delivery formulations. (2023) · cites this paper as [176]
Cited by
Sorted by citations
Euthyroid Sick Syndrome: Is It a Misnomer?
Chopra, I. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3745 · Cited by 374 · see citing works
Self-citationA review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism
Colucci, P., Yue, C. S., Ducharme, M., Benvenga, S., Principal Scientist, L. A. C. I., Principal Scientist, L. A. C. I. A. P. C., President and CEO, L. A. C. I., & Professor of Medicine, D. (2010) · European Endocrinology · doi:10.17925/ee.2013.09.01.40 · Cited by 167 · see citing works
Thyroid Hormones, Dementia, and Atrophy of the Medial Temporal Lobe
de Jong, F. J., den Heijer, T., Visser, T. J., de Rijke, Y. B., Drexhage, H. A., Hofman, A., & Breteler, M. M. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0449 · Cited by 129 · see citing works
Levothyroxine: conventional and novel drug delivery formulations.
Liu, H., Li, W., Zhang, W., Sun, S., & Chen, C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac030 · Cited by 63 · see citing works
Peeters, R. P., Kester, M. H. A., Wouters, P. J., Kaptein, E., van Toor, H., Visser, T. J., & Van den Berghe, G. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0866 · Cited by 57 · see citing works
Santini, F., Giannetti, M., Ricco, I., Querci, G., Saponati, G., Bokor, D., Rivolta, G., Bussi, S., Braverman, L. E., Vitti, P., et al. (2014) · Endocrine Practice · doi:10.4158/ep13331.or · Cited by 31 · see citing works
Self-citationSantini, F., Ceccarini, G., Pelosini, C., Giannetti, M., Ricco, I., Querci, G., Grossi, E., Saponati, G., & Vitti, P. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00826 · Cited by 17 · see citing works
Self-citation
- Authors
- Santini, F., Chiovato, L., Bartalena, L., Lapi, P., Palla, R., Panichi, V., Velluzzi, F., Grasso, L., Chopra, I. J., Martino, E., & Pinchera, A.
- Affiliations
- University of Pisa (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- University of Cagliari (IT)
- University of California, Los Angeles (US)
- Corresponding author
- Santini, Ferruccio
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-01
- Volume
- 134
- Issue
- 1
- Pages
- 45-49
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2078560780
- Cited by
- 28
- References
- 0
- Citations by year
- 2022: 1 · 2019: 1 · 2018: 1 · 2014: 1 · 2012: 3
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Funders
- Centre National de la Recherche Scientifique
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- chronic kidney disease, reverse T3, type I iodothyronine deiodinase, inorganic sulfate, thyroid hormone metabolism
- MeSH terms
- Adult, Aged, Humans, Kidney Failure, Chronic, Middle Aged, Neoplasms, Osmolar Concentration, Triiodothyronine, Triiodothyronine, Reverse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review